Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial
Article Information
vol. 41 no. 5 1009-1016
PubMed
Published By
Print ISSN
Online ISSN
History
- Received June 5, 2017
- Accepted February 5, 2018
- Published in print April 20, 2018.
- Published online ahead of print February 26, 2018.
Article Versions
- Previous version (February 26, 2018 - 07:04).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2018 by the American Diabetes Association. http://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.
Author Information
- Liana K. Billings1,2⇑,
- Ankur Doshi3,
- Didier Gouet4,
- Alejandra Oviedo5,
- Helena W. Rodbard6,
- Nikolaos Tentolouris7,
- Randi Grøn8,
- Natalie Halladin8 and
- Esteban Jodar9
- 1NorthShore University HealthSystem, Evanston, IL
- 2University of Chicago Pritzker School of Medicine, Chicago, IL
- 3PrimeCare Medical Group, Houston, TX
- 4La Rochelle Hospital, La Rochelle, France
- 5Santojanni Hospital and Cenudiab, Ciudad Autonoma de Buenos Aires, Argentina
- 6Endocrine and Metabolic Consultants, Rockville, MD
- 7Medical School, National and Kapodistrian University of Athens, Athens, Greece
- 8Novo Nordisk A/S, Søborg, Denmark
- 9H. U. QuirónSalud Madrid y Ruber Juan Bravo, Universidad Europea de Madrid, Madrid, Spain
- Corresponding author: Liana K. Billings, lbillings{at}northshore.org.
Statistics from Altmetric.com
Article usage
In this Issue
May 2018, 41(5)
Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial
